PARP inhibitors are drugs targeting the DNA-repairing enzyme PARP1, used in treating ovarian and breast cancer. With ongoing R&D, their future use is expected to expand.

Vittoria Biotherapeutics Reveals US FDA Approval of Investigational New Drug Submission for VIPER-101 to Address T-Cell Lymphoma Therapy.

Determining the causal relationship between a drug and a suspected adverse reaction is sometimes very difficult and takes a long time.

Bio-Thera Solutions, Ltd has made public the approval of their product Avzivi® (bevacizumab-tnjn) by the United States Food and Drug Administration.

Plasminogen activators inhibitors are substances that regulate clotting by inhibiting enzymes that break down blood clots.

ExeGi Pharma, a biopharmaceutical pioneer in live biotherapeutics, has commenced patient enrollment for its pivotal PROF Trial to test EXE-346, a new treatment targeting frequent bowel movements post ileal pouch-anal anastomosis surgery.

After the "Thalidomide Incident" in the 1960s, regulatory authorities in many countries established voluntary reporting systems for adverse drug reactions to collect adverse drug reactions.

Pfizer Inc. has released an announcement that the European Commission has provided a conditional marketing approval for their product, ELREXFIO (elranatamab).

As an important regulator of cAMP signal transduction, the PDE4 family has become a research hotspot for various diseases in recent years.

Vertex and CRISPR Therapeutics have declared that CASGEVY™ has been officially sanctioned by the FDA to combat sickle cell disease.

Drug recall means that drug manufacturers recall drugs that have been sold on the market and have potential safety hazards in accordance with prescribed procedures.

DAN-222 from Dantari has exhibited encouraging results in shrinking tumors for those suffering from advanced breast cancer that lacks the HER2 protein.